Hypertrophic cardiomyopathy laboratory findings: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 5: Line 5:


==Overview==
==Overview==
Genetic studies may be used in the diagnosis and screening of patients and families with known hypertrophic cardiomyopathy (HCOM).  Laboratory findings consistent with the diagnosis of hypertrophic cardiomyopathy may include but not limited to mutations in the genes involved in [[Myosin|Beta-myosin heavy chain]], [[Myosin]] binding protein C, and [[Cardiac troponin|Cardiac troponin T]].Genes involved in the [[pathogenesis]] of [[hypertrophic cardiomyopathy]] include [[MYH7]], [[TNNT2]], [[TPM1|and TPM1]].         
Genetic studies may be used in the diagnosis and screening of patients and families with known hypertrophic cardiomyopathy (HCOM).  Laboratory findings consistent with the diagnosis of hypertrophic cardiomyopathy may include but not limited to mutations in the genes involved in [[Myosin|Beta-myosin heavy chain]], [[Myosin]] binding protein C, and [[Cardiac troponin|Cardiac troponin T]]. Genes involved in the [[pathogenesis]] of [[hypertrophic cardiomyopathy]] include [[MYH7]], [[TNNT2]], [[TPM1|and TPM1]].         


==Laboratory Findings==
==Laboratory Findings==


Genetic studies may be used in the diagnosis and screening of patients and families with known hypertrophic cardiomyopathy (HCOM).  Laboratory findings consistent with the diagnosis of hypertrophic cardiomyopathy may include but not limited to mutations in the genes involved in [[Myosin|Beta-myosin heavy chain]], [[Myosin]] binding protein C, and [[Cardiac troponin|Cardiac troponin T]].Genes involved in the [[pathogenesis]] of [[hypertrophic cardiomyopathy]] include [[MYH7]], [[TNNT2]], [[TPM1|and TPM1]].       
Genetic studies may be used in the diagnosis and screening of patients and families with known hypertrophic cardiomyopathy (HCOM).  Laboratory findings consistent with the diagnosis of hypertrophic cardiomyopathy may include but not limited to mutations in the genes involved in [[Myosin|Beta-myosin heavy chain]], [[Myosin]] binding protein C, and [[Cardiac troponin|Cardiac troponin T]]. Genes involved in the [[pathogenesis]] of [[hypertrophic cardiomyopathy]] include [[MYH7]], [[TNNT2]], [[TPM1|and TPM1]].       


'''ESC recommendations for genetic counseling and testing'''
'''ESC recommendations for genetic counseling and testing'''

Revision as of 20:26, 17 January 2020

Hypertrophic Cardiomyopathy Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hypertrophic Cardiomyopathy from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hypertrophic cardiomyopathy laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hypertrophic cardiomyopathy laboratory findings

CDC on Hypertrophic cardiomyopathy laboratory findings

Hypertrophic cardiomyopathy laboratory findings in the news

Blogs on Hypertrophic cardiomyopathy laboratory findings

Directions to Hospitals Treating Hypertrophic cardiomyopathy

Risk calculators and risk factors for Hypertrophic cardiomyopathy laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Soroush Seifirad, M.D.[2]

Overview

Genetic studies may be used in the diagnosis and screening of patients and families with known hypertrophic cardiomyopathy (HCOM). Laboratory findings consistent with the diagnosis of hypertrophic cardiomyopathy may include but not limited to mutations in the genes involved in Beta-myosin heavy chain, Myosin binding protein C, and Cardiac troponin T. Genes involved in the pathogenesis of hypertrophic cardiomyopathy include MYH7, TNNT2, and TPM1.

Laboratory Findings

Genetic studies may be used in the diagnosis and screening of patients and families with known hypertrophic cardiomyopathy (HCOM). Laboratory findings consistent with the diagnosis of hypertrophic cardiomyopathy may include but not limited to mutations in the genes involved in Beta-myosin heavy chain, Myosin binding protein C, and Cardiac troponin T. Genes involved in the pathogenesis of hypertrophic cardiomyopathy include MYH7, TNNT2, and TPM1.

ESC recommendations for genetic counseling and testing

  • 1. Genetic counseling by trained professionals working within a multidisciplinary specialist team is recommended for all patients with HCM when their disease cannot be explained solely by a non-genetic cause.
  • 2. Genetic testing is recommended in patients fulfilling diagnostic criteria for HCM when it enables cascade genetic screening of their relatives.
  • 3. First degree relatives should be provided with information about the consequences of diagnosis for life insurance, pension, occupation, sporting activities, and eligibility for fostering and adoption before they undergo genetic testing or clinical evaluation.
  • 4. When a definite causative genetic mutation is identified, relatives should be first genetically tested and then clinically evaluated if they are found to carry the same mutation.
  • 5. When genetic testing cannot be performed or fails to identify a definite mutation, first degree relatives should be offered clinical screening with an ECG and echocardiogram which is then repeated every 1-2 years between 10 and 20 years of age and then every 2-5 years thereafter.
  • 6. Clinical and genetic testing of children should be guided by the best interests of the child and consider potential benefits and harms such as compromised life insurance prospects.


References

Template:WH Template:WS